NHAS
BBOT

Novo Holdings A/S’s BridgeBio Oncology BBOT Stock Holding History

Novo Holdings A/S’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.6M Buy
2,185,923
+224,606
+11% +$2.41M 1.59% 19
2025
Q4 		$24.6M Hold
1,961,317
– – 1.91% 19
2025
Q3 		$22.7M Buy
+1,961,317
New +$20.4M 1.46% 21

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Novo Holdings A/S's BBOT Position: Q1 2026 in Review

Novo Holdings A/S increased its BridgeBio Oncology (BBOT) stake by 11% in Q1 2026, buying an estimated $2.41M and bringing the position to 2,185,923 shares worth $19.6M. The position accounts for 1.59% of the portfolio, ranked #19.

Novo Holdings A/S first reported a position in BBOT in Q3 2025 and has held it in 3 quarters since. The position peaked at $24.6M in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Novo Holdings A/S held 2,185,923 shares of BridgeBio Oncology worth $19.6M as of Q1 2026.
  • Novo Holdings A/S bought 224,606 BridgeBio Oncology shares in Q1 2026, an estimated $2.41M.
  • BridgeBio Oncology made up 1.59% of Novo Holdings A/S's portfolio in Q1 2026, its #19 holding.
  • Novo Holdings A/S first reported a position in BridgeBio Oncology in Q3 2025 and has held it in 3 quarters since.
  • Novo Holdings A/S's BridgeBio Oncology position peaked at $24.6M in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Novo Holdings A/S's 13F filing for Q1 2026, filed 15 May 2026.